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Multidrug resistance (MDR) in tumors and pathogens remains a major problem in
the efficacious treatment of patients by reduction of therapy options and subsequent
treatment failure. Various mechanisms are described to be involved in the development
of MDR with overexpression of ATP-binding cassette (ABC) transporters reflecting the
most extensively studied. These membrane transporters translocate a wide variety
of substrates utilizing energy from ATP hydrolysis leading to decreased intracellular
drug accumulation and impaired drug efficacy. One treatment strategy might be
inhibition of transporter-mediated efflux by small molecules. Isocoumarins and 3,4-
dihydroisocoumarins are a large group of natural products derived from various sources
with great structural and functional variety, but have so far not been in the focus
as potential MDR reversing agents. Thus, three natural products and nine novel
3,4-dihydroisocoumarins were designed and analyzed regarding cytotoxicity induction
and inhibition of human ABC transporters P-glycoprotein (P-gp), multidrug resistance-
associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) in a variety of
human cancer cell lines as well as the yeast ABC transporter Pdr5 in Saccharomyces
cerevisiae. Dual inhibitors of P-gp and BCRP and inhibitors of Pdr5 were identified,
and distinct structure-activity relationships for transporter inhibition were revealed. The
strongest inhibitor of P-gp and BCRP, which inhibited the transporters up to 80 to
90% compared to the respective positive controls, demonstrated the ability to reverse
chemotherapy resistance in resistant cancer cell lines up to 5.6-fold. In the case of
Pdr5, inhibitors were identified that prevented substrate transport and/or ATPase activity
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with IC50 values in the low micromolar range. However, cell toxicity was not observed.
Molecular docking of the test compounds to P-gp revealed that differences in inhibition
capacity were based on different binding affinities to the transporter. Thus, these small
molecules provide novel lead structures for further optimization.
Keywords: multidrug resistance, cancer chemotherapy, 3,4-dihydroisocoumarin, P-glycoprotein, breast cancer
resistance protein, Pdr5
INTRODUCTION
Cancer remains the second most common cause of death
worldwide with 8.7 million deaths in 2015 (Fitzmaurice et al.,
2017). Despite constant progress in antitumor drug development,
multidrug resistance (MDR) poses a major problem in effective
patient treatment. MDR is estimated to cause treatment failure
in about 90% of patients with recurrent tumors (Longley and
Johnston, 2005). Additionally, it becomes a more and more
severe problem in the treatment of pathogens. In general, MDR
encompasses intrinsic or acquired resistance of cancer cells or
pathogens to a spectrum of drugs, finally leading to reduction
of treatment options and to therapy failure. Several mechanisms
mediating MDR have been described, including mutations in
drug targets, alterations in drug metabolism, decreased uptake
or increased efflux of the drug (Kaye and Kaye, 2000; Gillet and
Gottesman, 2010).
Probably the most prominent and widespread mechanism
in eukaryotic cells is covered by increased drug transport from
the cytoplasm through overexpression of ATP-binding cassette
(ABC) transporters (El-Awady et al., 2016). The ABC transporter
superfamily, representing one of the oldest and largest protein
families, is expressed from archaea to human. The common
mechanism for all ABC transporters encompasses the active
membrane translocation of a broad spectrum of substrates using
energy from ATP hydrolysis (Szöllõsi et al., 2017).
Regarding MDR development accompanying antitumor
therapy, three ABC transporters were identified as the main
contributors in humans. P-glycoprotein (P-gp, ABCB1),
multidrug resistance-associated protein 1 (MRP1, ABCC1) and
breast cancer resistance protein (BCRP, ABCG2) are frequently
overexpressed in chemotherapy-resistant tumors, where they
facilitate resistance to wide varieties of drugs commonly
used in clinical practice (Bugde et al., 2017). Furthermore,
recent studies have shown a pronounced influence of ABC
transporters in drug resistance mechanisms controlled by cancer
stem cells, mainly responsible for recurrence of the disease
(Begicevic and Falasca, 2017).
The ABC transporter Pdr5 from Saccharomyces cerevisiae
is located in the plasma membrane (PM) and acts in
combination with other exporter pumps as a first line of defense
against structurally unrelated xenobiotic compounds forming the
pleitropic drug resistance (PDR) network (Ernst et al., 2005).
Pdr5 is the most abundant exporter pump in yeast and highly
homologous to multidrug mediating transporters of clinical
relevant fungi such as Candida albicans. Each year billions of
people become infected with pathogenic fungi and 1.5 million
people are killed because of that (Brown et al., 2012). One of
the largest problems is the evolving resistance shift of several
fungi against azoles, which prevent one of the most efficient
treatments. Therefore, the development of new antifungal drugs
is of great importance.
Since the discovery of ABC transporter and characterization of
their significant contribution to MDR, pharmacological strategies
to overcome transporter-mediated MDR have been in the focus
of various drug discovery approaches (Szakács et al., 2006;
Tillotson and Theriault, 2013). One focus is the development
of small molecule inhibitors interfering with transporter activity
in combination with chemotherapeutic drugs, thereby increasing
intracellular drug accumulation and efficacy by reversing
resistance (Zhang and Ma, 2010; Spengler et al., 2017; Tran-
Nguyen et al., 2017). ABC transporters involved in MDR
often have overlapping substrate spectra. For example, several
tyrosine kinase inhibitors including dasatinib and imatinib were
demonstrated to become translocated to the extracellular space
by P-gp and BCRP (Dohse et al., 2010). This leads to reduced
efficacy of those drugs and subsequent therapy failure.
In most tumors, MDR is not only mediated by overexpression
of one ABC transporter, but by expression of several transporters.
Furthermore, P-gp and BCRP are co-expressed at the blood–
brain barrier and prevent effective treatment of brain tumors
(Agarwal et al., 2011). Hence, the design of dual transporter
inhibitors appears to be more efficacious in mentioned cases.
To date, several dual inhibitors of P-gp and BCRP have been
identified including tariquidar and derivatives, aurones and
chalcones (Sim et al., 2011; Gu et al., 2014; Li et al., 2015).
Tariquidar entered clinical trials up to phase II to circumvent
P-gp mediated MDR, but did not reveal sufficient clinical activity
(Pusztai et al., 2005).
Natural compounds and their derivatives play an important
role in drug discovery and development (Newman and Cragg,
2016; Guo, 2017). In this context, various ABC transporter
inhibitors from natural sources were identified and characterized
in the last decades (Karthikeyan and Hoti, 2015). Early natural
product P-gp inhibitors such as cyclosporine A or its synthetic
derivative PSC833 were tested in clinical trials up to phase
III, but failed due to toxicity or other unintended side effects
(Warner et al., 1995; Baer et al., 2002). Among them were several
dual inhibitors of P-gp and BCRP, for example some aurones,
chalcones or flavonoids (Boumendjel et al., 2009; Sim et al., 2011;
Yuan et al., 2012; Iriti et al., 2017).
Isocoumarins, isomers of coumarin, represent a large class
of secondary metabolites, which can be found in bacteria,
fungi, lichens, marine sponges and to a lesser extent in higher
plants (Saeed, 2016). To date, several 100 different isocoumarins
and dihydroisocoumarins from nature have been identified and
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derivatives have been synthesized. Owing to their great structural
diversity, diverse biological and pharmacological activities of
isocoumarins including cytotoxicity and antimetastatic effects
against various cancer types including breast, colon, melanoma
(Cichewicz et al., 2004; Abid et al., 2012; Guimarães et al., 2016;
Zhang et al., 2017), inhibition of inflammation (Liang et al., 2011;
Ramanan et al., 2016) or different enzymes including aromatase
and kallikrein peptidases as potential cancer targets (Endringer
et al., 2008; Teixeira et al., 2011) as well as antibacterial,
antifungal and antimalarial activities (Hoepfner et al., 2012;
Lai et al., 2016; Simic et al., 2016) could be identified. Several
natural or synthetic coumarins were identified as inhibitors of
either P-gp, BCRP or both, yet activities were mostly moderate,
and compound concentrations between 10 and 100 µM had
to be applied for transporter inhibition (Barthomeuf et al.,
2005; Raad et al., 2006; Combes et al., 2011; Bisi et al.,
2017; Sjöstedt et al., 2017). In contrast, isocoumarins have
to our knowledge not been characterized as potential MDR-
reversing agents to date.
In this study, the three natural compounds 6-methoxymellein
(3), angelicoin B (4) and ellagic acid as well as nine novel 3,4-
dihydroisocoumarins (Figure 1) were analyzed regarding their
cytotoxicity in cancer cells and inhibition of the endogenously
expressed human ABC transporters P-gp, BCRP, and MRP1
and of the yeast transporter Pdr5. For further insights into
the mechanism of action, Pdr5 ATPase and substrate transport
assays were performed. These results were complemented with
molecular docking studies that indicate that differences in the
inhibitory power of the investigated 3,4-dihydroisocoumarins
with respect to P-gp-mediated transport result from differences
in the compounds’ binding affinities to P-gp.
MATERIALS AND METHODS
Chemicals and Reagents
A549 and HCT-15 cells were purchased from the German
Collection of Microorganisms and Cell Cultures (Braunschweig,
Germany) and H69AR cells from the American Type Culture
Collection (Manassas, VA, United States). Dr. Erasmus Schneider
(Wadsworth Center, New York State Department of Health,
Albany, NY, United States) kindly provided the MCF-7/MX
cells. Cell culture media and supplements were purchased from
Thermo Fisher Scientific (Waltham, MA, United States). Yeast
extract, peptone, and D-glucose were purchased from Carl Roth
(Karlsruhe, Germany). Hoechst 33342, rhodamine 6G (R6G)
and adenosine 5′-triphosphate (ATP) were purchased from
Sigma-Aldrich (St. Louis, MO, United States) and dissolved
in water. Calcein-AM, PSC833, Ko143, MK-571, doxorubicin,
mitoxantrone, and ketoconazole (Sigma-Aldrich, St. Louis, MO,
United States) were dissolved in dimethyl sulfoxide (DMSO; Carl
Roth, Karlsruhe, Germany or Acros Organics, Geel, Belgium).
Hepes buffer was purchased from Lonza (Basel, Switzerland).
CellTiter-Glo Luminescent Cell Viability Assay was purchased
from Promega (Madison, WI, United States). Microtiter plates
were purchased from Greiner Bio-One (Kremsmünster, Austria)
or Falcon (Corning, NY, United States).
Test Compounds
3,4-Dihydroisocoumarins were synthesized in three steps starting
from α,β-unsaturated δ-lactones (Fischer and Pietruszka, 2007;
Böse et al., 2014) and freshly prepared Brassard’s diene. The
reaction was catalyzed by AlMe3 as Lewis acid and Tf2CH2 as
Brønsted acid leading to the major vinylogous (E)-configured
Michael-product and the minor cyclic product. The isolated (E)-
configured Michael-product was cyclized with the strong base
lithium bis(trimethylsilyl)amide (LHMDS) at −78◦C to room
temperature for 16 h. Both fractions of the isochromenones
from the first and second step were oxidized with 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in toluene at
room temperature for 4 h to the desired end product. Overall
yields were between 30 and 84%.
Deprotection of isocoumarins (R)-19 and (S)-19 by boron
trifluoride diethyl ether in dichloromethane at 0◦C gave (R)-
19a and (S)-19a in good to moderate yields between 36 and
47%. The free hydroxy-groups of the pentyl-derivative 16 and the
unsubstituted isocoumarin 14 were protected by dimethylsulfate.
This procedure gave 66% of the corresponding methyl-protected
pentyl-isocoumarin 16a and 51% of the methyl-protected
isocoumarin 14a.
Ellagic acid was provided by MicroCombiChem
GmbH (Wiesbaden, Germany). All test compounds were
dissolved in DMSO.
Cell Culture
Human Cancer Cell Lines
The human lung adenocarcinoma cell line A549 was cultured
in DMEM medium supplemented with 10% fetal bovine serum
(FBS), 100 U/mL penicillin and 100 µg/mL streptomycin.
P-gp-expressing human colon adenocarcinoma cells HCT-15
were cultured in RPMI 1640 medium supplemented with
10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin.
BCRP-expressing MCF-7/MX human breast adenocarcinoma
cells were cultured in DMEM medium supplemented with
10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin.
MRP1-expressing H69AR human small cell lung cancer cells
were cultured in RPMI 1640 medium (ATCC modification)
supplemented with 20% FBS, 100 U/mL penicillin and
100 µg/mL streptomycin. All cancer cell lines employed
have been systematically characterized regarding their respective
ABC transporter expression profile (Sachs et al., 2019).
Cells were maintained in a humidified atmosphere at 37◦C and
5% CO2 and subcultured when confluency reached 80 to 90%.
Yeast Strain
The following S. cerevisiae yeast strain was used: YRE1001
(MATa ura3-52 trp1-1 leu2-3,112 his3-11,15 ade2-1 pdr1-3
pdr5pdr5prom1::TRP1). S. cerevisiae was cultured in YPD
medium (10 g/L yeast extract, 20 g/L peptone, 2% glucose)
at 30◦C and 200 rpm. The yeast strain has been described
previously (Ernst et al., 2008; Gupta et al., 2014). Based on
these studies it is evident that Pdr5 localizes to the PM and is
present in approximately 10% of the overall membrane protein
content of the PM.
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FIGURE 1 | Structures of natural and synthetic 3,4-dihydroisocoumarins.
Cell Viability Assay
Cytotoxic activity of test compounds was analyzed after
48 h using the CellTiter-Glo Luminescent Cell Viability Assay
published previously (Weber et al., 2017) in 384-well plates with
the following cell densities: A549, MCF-7/MX: 2× 103 cells/well;
HCT-15: 3 × 103 cells/well; H69AR: 5 × 103 cells/well. Pipetting
was conducted with the CyBi-Well 96-channel simultaneous
pipettor (Analytik Jena AG, Jena, Germany). For generation of
dose-response curves and calculation of IC50 values, the four-
parameter logistic model was applied.
The ability of identified inhibitors of P-gp and BCRP to
sensitize HCT-15 or MCF-7/MX cells to chemotherapy was
analyzed by co-treatment with test compounds and doxorubicin
or mitoxantrone, respectively. Cells were incubated with a serial
dilution of the chemotherapeutic drug alone or in combination
with fixed concentrations of the test compounds or positive
controls (2.5 µM PSC833 and 1 µM Ko143, respectively). Fold
change of drug IC50 was calculated with the formula IC50 (drug
alone)/IC50 (drug with modulator).
Liquid Drug Assay
The liquid drug assay was carried out in sterile 96-well plates.
50 µl of yeast cell culture at an OD600 of 0.15 were mixed with
193.75 µl YPD and 6.25 µl of the test compound or DMSO as
a negative control. To distinguish between cytotoxic compounds
and those which inhibit Pdr5 WT specifically, the Pdr5 substrate
ketoconazole was added only to cultures expressing wild-type
Pdr5 in a final concentration of 1 µg/ml. At this concentration,
inhibition of Pdr5 would result in ketoconazole-mediated cell
death. After 48 h at 30◦C the growth was measured with an ELISA
plate reader (BioRad, Hercules, CA, United States) at 595 nm.
Isolation of Pdr5 Containing
Plasma Membranes
Saccharomyces cerevisiae cells expressing Pdr5 WT or the E1036Q
(EQ) mutant were cultured to an OD600 of 1.5 in YPD-media at
25◦C. The nitrogen source was replenished by addition of a 10th
volume of 5x YP (50 g/l yeast extract, 100 g/l peptone). The cells
were grown to an OD of 3.5 and harvested (5000 × g at 4◦C for
15 min). The isolation of Pdr5 containing PMs was performed as
described (Kolaczkowski et al., 1996; Ernst et al., 2008).
Inhibition of ABC Transporter Activities
P-gp Transport Assay
The transport of calcein-AM by P-gp and its modulation by
test compounds was analyzed in the P-gp-expressing HCT-15
cell line. 5 × 104 cells were seeded in black 96-well plates
and incubated at 37◦C and 5% CO2 for 24 h. The culture
medium was removed and replaced by Hank’s balanced salt
solution supplemented with 10 mM HEPES. Test compounds,
2.5 µM PSC833 (positive control) or 0.5% DMSO (negative
control) were added in triplicates and incubated for 30 min at
37◦C and 5% CO2. The substrate calcein-AM was added (final
concentration 0.5 µM) and the fluorescence (excitation 485 nm,
emission 520 nm) was measured over 3 h with the Infinite
m1000 pro microplate reader (Tecan Group AG, Männedorf,
Switzerland) at 37◦C. The transport activity of P-gp was analyzed
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by determining the slope of the linear part of the fluorescence-
time curve (0–30 min) using linear regression. Normalization
of the data to PSC833 (100% inhibition) and DMSO (0%
inhibition) was performed.
BCRP Transport Assay
Breast cancer resistance protein transport activity was
determined in the BCRP-expressing MCF-7/MX cell line.
Hoechst 33342 was applied as transporter substrate and 1 µM
Ko143 as positive control or 0.5% DMSO as negative control
and the assay was performed according to the P-gp assay.
Fluorescence was measured at an excitation wavelength of
355 nm and emission wavelength of 460 nm. The transport
activity of BCRP was analyzed by determining the plateau of
the fluorescence-time curve by using non-linear regression
(one-phase exponential fit). Normalization of the data to Ko143
(100% inhibition) and DMSO (0% inhibition) was performed.
MRP1 Transport Assay
Transport activity of MRP1 was determined in MPR1-expressing
H69AR cells using the substrate calcein-AM and 20 µM MK-
571 as the positive control or 0.5% DMSO as negative control.
Experimental procedure was according to the P-gp assay, except
that 7.5× 104 cells were seeded per well. The transport activity of
MRP1 was analyzed by determining the slope of the linear part of
the fluorescence-time curve (0–20 min) using linear regression.
Normalization of the data to MK-571 (100% inhibition) and
DMSO (0% inhibition) was performed.
Pdr5 Transport Assay
Active transport of R6G was measured according to the protocol
developed by Kolaczkowski et al. (1996), using a Tecan Infinite
200 pro reader (Tecan Group AG, Männedorf, Switzerland). 6 µg
of the isolated PM containing Pdr5 were resuspended in 200 µl
of the transport buffer (50 mM HEPES, pH 7.0, 5 mM MgCl2,
10 mM NaN3, and 150 nM R6G) and incubated in a black 96-
well plate at 30◦C. 5 µl of the test compound were added at the
indicated concentrations. Active transport was initiated by the
addition of 10 µl 200 mM ATP and fluorescence intensity was
recorded in 15 s-intervals for 20 min (excitation wavelength at
524 nm, emission wavelength at 558 nm, number of flashes 30,
integration time 2000 µs). IC50 determination was performed
with a serial dilution of the test compounds.
Pdr5 ATPase Assay
Oligomycin (OM)-sensitive ATPase activity was measured from
0.8 µg PM containing Pdr5 incubated with 2 mM ATP, 5 mM
MgCl2 in 270 mM TRIS-glycine buffer (pH 9.5) and 2.5 µl of
the test compounds or DMSO as a control in a total volume of
100 µl. To reduce the background activities, 0.2 mM ammonium
molybdate, 10 mM NaN3 and 50 mM KNO3, respectively, were
added (Dufour et al., 1988; Goffeau and Dufour, 1988). In a
second assay, OM (20 µg/ml) was added to an otherwise identical
setup. After incubation at 30◦C for 20 min, the reaction was
stopped by adding 25 µl of the reaction to 175 µl 40 mM H2SO4.
The amount of released inorganic phosphate was determined by
a colometric assay in 96-well plates (Goffeau and Dufour, 1988;
Decottignies et al., 1994; Wada et al., 2002). The difference of
both assays ( ± OM) corresponds to the specific ATPase activity
of Pdr5 (Ernst et al., 2008).
Molecular Docking Studies
The cryo-EM structure of P-gp (PDB ID: 6FN1, chains A and B)
(Alam et al., 2018) was prepared for molecular docking using the
Protein Preparation Wizard (Sastry et al., 2013) as implemented
in the Maestro GUI1 of the Schrödinger Suite version 2018-
21. Protonation states for Asp, Glu, His and Lys, tautomers for
His and chi flips for Asp, Glu, and His were calculated at pH
7.4 with the PROPKA (Olsson et al., 2011; Søndergaard et al.,
2011) implementation in Maestro. Subsequently, a restrained
energy minimization was performed on all hydrogen atoms. To
be able to use the structure for later MM-GBSA calculations with
implicit membrane, the coordinates of the prepared structure
were superimposed onto the coordinates of its respective OPM
(Lomize et al., 2012) entry. The membrane region was then
defined in the Maestro GUI, using the membrane dimensions of
31.4 Å calculated by the PPM server (Lomize et al., 2012).
Molecular docking was performed using the Glide XP docking
protocol (Friesner et al., 2004, 2006) of the Schrödinger Suite
version 2018-2. To allow more poses to pass through the
initial Glide screens, the initial number of poses per ligand
was increased from 5,000 to 50,000 and the scoring window
was widened from 100.0 to 500.0. In addition, the number of
minimized poses per ligand was increased from 400 to 1,000
and the ‘expanded sampling’ option was enabled. Post-docking
minimization was performed on 100 poses, and the resulting best
10 poses per ligand were kept for further evaluation.
Four re-docking experiments were performed to assess the
suitability of the selected docking approach: two re-dockings
were performed in the presence of the respective other ligand
entity (re-docking 1), and two re-dockings were performed in
which both ligand entities were docked sequentially (re-docking
2). For re-docking 1, the size of the region in which the geometric
center of the ligand can move during docking (‘inner box’) was
set to 10 Å, and the size of the region in which ligand atoms
may be placed during docking (‘outer box’) was set such that
it expands the size of the inner box by 17 Å. For re-docking
2, the center and size of the inner box was set to match the
center and size of the smallest possible cuboid that encloses
both ligands in the cryo-EM complex. The size of the outer
box was set such that it expands the size of the inner box by
15 Å. The same box as for re-docking 2 was also used for
the docking of the 3,4-dihydroisocoumarins. Since this docking
procedure produced favorably scored poses in two different
binding sites, the dockings were repeated for each of these
binding sites individually, using docking boxes centered on the
geometric center of the poses generated in the corresponding
binding pocket. For these dockings, the box sizes were set as
for re-docking 1.
In order to obtain a more reliable estimate of the relative
affinities of the 3,4-dihydroisocoumarins, for each of the two
binding sites, the best scored pose of each docked ligand
1https://www.schrodinger.com/citations
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was post-processed using the MM-GBSA implementation in
Prime (see footnote number 1) with the VSGB 2.1 solvation
model (Jianing et al., 2011). During this procedure, protein
flexibility was taken into account for all residues within 8 Å
of the ligand pose. Contributions due to changes in the
configurational entropy of the ligand or the receptor upon
complex formation were neglected, in order to avoid introducing
uncertainty in the computations (Gohlke and Case, 2004; Weis
et al., 2006; Hou et al., 2011). For compounds 16 and 16a,
the final effective binding energy was expressed as the average
over the effective binding energies for both enantiomers. All
effective binding energies were then converted to relative effective
binding energies.
Data Analysis and Statistics
All experiments were performed in at least three independent
replicates. Data were analyzed with GraphPad Prism v. 6.07
(GraphPad Software, Inc., La Jolla, CA, United States) and
results are presented as mean ± SEM. Different groups were
compared statistically using one-way ANOVA followed by
Dunnett’s multiple comparisons test. Differences were considered
significant when p< 0.05.
RESULTS
Cytotoxic Activity of
3,4-Dihydroisocoumarins in Human
Cancer Cell Lines
Cytotoxicity of 12 3,4-dihydroisocoumarins was analyzed in the
sensitive lung cancer cell line A549 as well as in three resistant
cell lines HCT-15 (colon carcinoma), MCF-7/MX (breast
carcinoma) and H69AR (lung carcinoma) either expressing
the ABC transporter P-gp, BCRP, or MRP1, respectively.
Cells were incubated for 48 h with test compounds and cell
viability was assessed.
IC50 values of the tested 3,4-dihydroisocoumarins are
summarized in Table 1. Most compounds did not display
significant cytotoxic activities in the cancer cell lines and IC50
values were above the highest concentrations applied in the
assay. However, one exception were the enantiomers (R)-19
and (S)-19. Both compounds displayed comparable cytotoxicity
in sensitive A549 cells and the BCRP-overexpressing MCF-
7/MX cells. In A549 cells, IC50 value of compound (R)-19 was
47.5 ± 3.2 µM (mean ± SEM) and IC50 value of (S)-19 was
42.0 ± 3.9 µM. In MCF-7/MX cells, both compounds were
slightly more toxic with IC50 values of 28.1 ± 0.7 µM and
33.5± 7.5 µM, respectively. In contrast, in P-gp expressing HCT-
15 cells, only (R)-19 demonstrated a cytotoxic effect, whereas
(S)-19 was not toxic. Furthermore, the unprotected derivatives of
(R)-19 and (S)-19, (R)-19a and (S)-19a, were analyzed. In both
cases, removal of the protecting TBS group led to complete or
near complete loss of cytotoxic activity in all cell lines.
Compound 16 was not cytotoxic in P-gp expressing HCT-
15 cells and BCRP-expressing MCF-7/MX cells. In MRP1-
expressing H69AR cells and sensitive A549 cells, only minor
TABLE 1 | Cytotoxicity of 3,4-dihydroisocoumarins on human tumor cell lines.
Compound IC50 (µM)
A549 HCT-15 MCF-7/MX H69AR
14 >100 >100 >100 >100
14a >100 >100 >100 >100
16 78.6 ± 2.2 >100 >100 88.5 ± 4.6
16a 53.6 ± 5.6 >100 10.6 ± 0.9 >100
(R)-19 47.5 ± 3.2 57.1 ± 7.5 28.1 ± 0.7 >100
(R)-19a >100 >100 >100 >100
(S)-19 42.0 ± 3.9 >100 33.5 ± 7.5 86.8 ± 9.2
(S)-19a >100 >100 89.8 ± 4.9 >100
6-Methoxymellein (3) >100 >100 >100 >100
Angelicoin B (4) >100 >100 >100 >100
21 >50 >50 >50 >50
Ellagic acid >50 >50 >50 >50
Data represent mean ± SEM of at least three independent experiments performed
in quadruplicates.
cytotoxic activity was observed. IC50 values were 88.5 ± 4.6 µM
and 78.6 ± 2.2 µM, respectively. Remarkably, the derivative
16a, which differs from 16 by the methoxy group instead of the
hydroxy group at position 8, displayed slightly improved activity
in A549 cells with an about 1.5-fold lower IC50 value and a
clearly improved activity in BCRP-expressing MCF-7/MX cells.
In those cells, the IC50 value was 10.6 ± 0.9 µM. In P-gp or
MRP1-expressing cell lines, no cytotoxicity could be observed.
The known natural products 6-methoxymellein (3), angelicoin
B (4) and ellagic acid did not show any cytotoxic effects against
the tested cancer cell lines.
Identification of
3,4-Dihydroisocoumarins as Dual
Inhibitors of P-gp and BCRP
The 12 3,4-dihydroisocoumarins were tested for their ability to
inhibit the transport activity of the human ABC transporters
P-gp, BCRP, and MRP1 in cell lines overexpressing the
respective transporter. Therefore, intracellular fluorescence of
the transporter substrates calcein-AM and Hoechst 33341 were
measured over time after cells had been treated with different
concentrations of the test compounds. Inhibition rates of the
compounds were normalized to the positive controls 2.5 µM
PSC833, 1 µM Ko143, and 20 µM MK-571, respectively. As
a result, three compounds were identified as dual inhibitors of
transport activity of P-gp and BCRP (Figures 2A,B).
Pentyl-derivative 16 was the strongest dose-dependent
inhibitor of P-gp and BCRP among the tested compounds.
Relative inhibition of P-gp was 36.3 ± 5.3% at a concentration
of 10 µM, 52.6 ± 3.1% at 20 µM and 81.2 ± 2.7% at 50 µM
(mean ± SEM). Regarding inhibition of BCRP, the rates were
comparable to P-gp with relative values between 35.3 ± 3.4%
at 10 µM and 89.1 ± 4.6% at 50 µM. Interestingly, derivative
16a, which differs from 16 only by the methoxy group instead
of the hydroxy group at position 8, showed reduced inhibition
rates against both transporters with a more pronounced effect
Frontiers in Pharmacology | www.frontiersin.org 6 April 2019 | Volume 10 | Article 400
fphar-10-00400 April 14, 2019 Time: 11:9 # 7
Sachs et al. 3,4-Dihydroisocoumarins Inhibit ABC Transporters
FIGURE 2 | Influence of 3,4-dihydroisocoumarins on ABC transporter activity. Cancer cell lines overexpressing (A) P-gp (HCT-15), (B) BCRP (MCF-7/MX), or
(C) MRP1 (H69AR) were incubated with test compounds and intracellular fluorescence of the substrates calcein-AM (P-gp, MRP1) or Hoechst 33342 (BCRP) was
measured over 3 h. Data were normalized to DMSO (0% inhibition) and the positive controls PSC833, Ko143, and MK-571, respectively (100% inhibition). Bars
represent mean ± SEM of at least three independent experiments. nd, not determined because of intrinsic fluorescence.
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for BCRP. Relative inhibition was between 18.4 ± 0.5 and
31.9± 2.2% for P-gp and 2.3± 0.9 and 14.9± 2.2% for BCRP.
Two additional compounds were identified as dual P-gp and
BCRP inhibitors, (R)-19 and (S)-19, but with lower activities
compared to derivative 16. Derivative (R)-19 inhibited P-gp with
relative rates between 23.6± 4.2 and 46.8± 5.7%. Regarding (S)-
19, highest P-gp inhibition was achieved at 10 µM (37.1± 2.9%).
Inhibition of BCRP was comparable. As both compounds contain
protective groups at the hydroxy group at the ethyl chain at
position 3, inhibition rates were compared to the deprotected
derivatives (R)-19a and (S)-19a. In both cases, the deprotected
compounds showed clearly reduced inhibitory ability of P-gp
with values between about 5 and 15% and completely abolished
inhibitory ability of BCRP.
Two compounds without substitution at position 3 were
analyzed, 14 and 14a. They only differ in the substituent at
position 8, which is either a hydroxy group 14 or methoxy
group 14a. Both compounds did not inhibit BCRP and displayed
only minor inhibitory activity against P-gp up to about 10%
relative inhibition.
Furthermore, the two natural products and enantiomers 6-
methoxymellein (3) and angelicoin B (4) were studied. They share
the same structure with compound 14, but are substituted with
a methyl group at position 3. Relative rates of P-gp inhibition
of 6-methoxymellein (3) and angelicoin B (4) did not differ
significantly from those of derivative 14. In case of BCRP,
no inhibitory activity could be observed, as was the case for
derivative 14.
Compound 21, a tricyclic derivative, weakly inhibited P-gp
with a relative inhibition rate of 20.0 ± 1.2% at the highest
concentration used. Its ability to inhibit BCRP could not be
determined due to inherent fluorescence. The natural product
ellagic acid did not display any inhibitory activity against
P-gp or BCRP. It has to be noted that this compound
could not be employed at a concentration of 50 µM due to
its low solubility.
Regarding inhibition of MRP1 transport function in
H69AR cells, none of the test compounds demonstrated any
activity (Figure 2C).
Sensitization of Resistant Cancer Cells
to Chemotherapy by
3,4-Dihydroisocoumarins
Cancer cells overexpressing MDR related ABC transporters
are characterized by reduced susceptibility to chemotherapeutic
drugs, which are substrates of the respective transporters. These
are for example doxorubicin (P-gp) and mitoxantrone (BCRP).
To determine if the identified P-gp and BCRP inhibitor derivative
16 is able to re-sensitize resistant cancer cells to chemotherapy,
P-gp expressing HCT-15 cells and BCRP-expressing MCF-7/MX
cells were co-treated with doxorubicin or mitoxantrone and
different concentrations of compound 16. IC50 values were
determined after 48 h and compared to single treatment with
the chemotherapeutic drugs. PSC833 (2.5 µM) and Ko143
(1 µM) served as respective positive controls for P-gp and
BCRP, respectively.
In both cases, compound 16 was able to significantly
sensitize the resistant cancer cells to chemotherapy. In HCT-
15 cells, doxorubicin alone had an IC50 value of 8.5 ± 0.7 µM
(mean ± SEM; Figure 3A and Table 2). Addition of 20 µM
of compound 16 did not lead to a change in IC50, whereas
the combination with 50 µM of the compound lead to a 3.7-
fold decrease in IC50 to 2.3 ± 0.1 µM. In contrast, compound
14, which displayed minor P-gp inhibiting activity, did not
sensitize the cells to doxorubicin. The positive control PSC833
reduced the IC50 of doxorubicin around 28-fold to a value of
0.35± 0.08 µM.
In BCRP-expressing MCF-7/MX cells, IC50 value of the drug
mitoxantrone alone was 19.6± 2.4 µM (Figure 3B and Table 3).
Addition of compound 16 revealed a dose-dependent decrease in
IC50 up to 5.6-fold at 50 µM to 3.5± 0.9 µM. As observed above,
compound 14, which did not inhibit BCRP transport function,
did not have a significant influence on the sensitivity of the cells
to mitoxantrone. The positive control Ko143 was able to increase
the cytotoxicity of mitoxantrone around 65-fold to an IC50 value
of 0.33± 0.07 µM.
Cytotocity of 3,4-Dihydroisocoumarins
on Pdr5 Wild-Type and Pdr5 EQ
Expressing Yeast Strains and Their
Ability to Inhibit Transport and ATPase
Activity of Pdr5 Wild-Type
The 12 3,4-dihydroisocoumarins were tested on two different
S. cerevisiae strains to determine their cytotoxicity on yeast.
Therefore, a Pdr5 WT and a Pdr5 EQ mutant overexpressing
strain were incubated with serial dilutions of the test compounds
and OD600 was measured after 48 h of cell growth at 30◦C. None
of the tested 3,4-dihydroisocoumarins showed an effect on the
growth of the cells (Figure 4), except compound 16a, which
inhibited the growth of the mutant strain slightly at the highest
tested concentration (Figure 4D). However, it had no effect on
the wild-type strain (Figure 4C).
In a first initial screen, the effect of the highest concentrations
(10 mM) of the 3,4-dihydroisocoumarins on R6G transport
and ATPase activity of Pdr5 in PM preparations was analyzed
(Figure 5). In the case of the transport assay, Pdr5 containing
PM preparations were incubated simultaneously with R6G
and the test compound. If Pdr5 actively transports R6G, the
concentration of the substrate increases in one of the membrane
leaflets, which leads to a self-quenching effect. This can be
measured as a decrease of fluorescence intensity in real time.
Compound 14, 6-methoxymellein (3) and angelicoin B (4) did
not interfere with Pdr5-mediated R6G transport (Figure 5A)
as the observed changes in fluorescence were comparable to
R6G transport of the wild-type protein in the absence of the
compound. In contrast, compounds 21, (R)-19a and (S)-19a
inhibited transport activity to 49, 43, and 37%, respectively. Only
compound (R)-19, (S)-19, 16 and 16a were able to inhibit the
transport of R6G completely.
Figure 5B summarizes the effect of the 3,4-
dihydroisocoumarins on ATPase activity of Pdr5 WT. Again,
compound 14, 6-methoxymellein (3) and angelicoin B (4) had
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FIGURE 3 | Sensitization of resistant cancer cells to chemotherapy by selected 3,4-dihydroisocoumarins. (A) P-gp expressing HCT-15 and (B) BCRP-expressing
MCF-7/MX were treated with either doxorubicin or mitoxantrone alone, in combination with positive controls PSC833 or Ko143 or in combination with varying
concentrations of test compounds 16 and 14. Cell viability was determined after 48 h. Data represent mean ± SEM normalized to untreated cells of at least three
independent experiments performed in quadruplicates.
no inhibitory effect. In contrast to the capability of (R)-19a and
(S)-19a to inhibit transport of R6G, no inhibition of the ATPase
activity was observed. Ellagic acid and compound 21 inhibited
the ATPase activity to 56 and 54%, respectively. Compounds
(R)-19, (S)-19, 16, and 16a showed the highest inhibition
potential on the Pdr5 WT ATPase activity.
Finally, IC50 values were determined for those inhibitors that
displayed the highest potential in the transport and the ATPase
assay ((R)-19, (S)-19, 16, and 16a) (Figures 6, 7). Figure 6
summarizes the IC50 measurements of the transport assays.
TABLE 2 | Sensitization of HCT-15 cells to doxorubicin treatment by selected
3,4-dihydroisocoumarins.
Compound IC50 (µM) p-Value Fold change
Doxorubicin 8.5 ± 0.7 – 1.00
+2.5 µM PSC833 0.3 ± 0.03∗∗ 0.0017 28.33
+20 µM 16 8.7 ± 1.6 0.9999 0.98
+50 µM 16 2.3 ± 0.08∗ 0.0129 3.70
+20 µM 14 9.6 ± 1.0 0.9498 0.89
+50 µM 14 10.6 ± 2.1 0.6313 0.80
PSC833 was used as positive control. Fold change of cytotoxicity was determined
by dividing the IC50 value of cells treated with doxorubicin alone by the IC50
value of cells treated with doxorubicin in combination with the respective test
compound. Data show mean ± SEM of three independent experiments performed
in quadruplicates. ∗p < 0.05; ∗∗p < 0.01 compared to doxorubicin alone (one-way
ANOVA followed by Dunnett’s multiple comparisons test).
The lowest IC50 was determined for compound (S)-19 with
5.3 ± 0.6 µM. Compound 16 and 16a showed IC50 values of
15.1 ± 2.1 and 14.6 ± 3.9 µM, respectively. The highest IC50
value was detected for compound (R)-19 with 26.0 ± 3.5 µM.
Figure 7 summarizes the IC50 measurements with respect to
inhibition of ATPase activity. Due to the solubility limit of
these compounds, no reliable determination of IC50 values
could be performed.
Binding Mode Prediction and Effective
Binding Energy Calculations on
Complexes of P-Glycoprotein and
3,4-Dihydroisocoumarins
The selected docking protocol was able to reproduce the binding
modes of Zosuquidar (ZQU) in P-gp, regardless of whether the
second ligand entity was retained in the structure (RMSDZQU1304:
0.93 Å, RMSDZQU1305: 1.14 Å, Figure 8A) or not (RMSDZQU1305:
1.53 Å, RMSDZQU1304: 3.21 Å, Figure 8B), suggesting that
it is also suitable for predicting the binding modes of other
molecules, such as the 3,4-dihydroisocoumarins. When two
molecules of ZQU were sequentially docked to the P-gp structure,
all poses obtained during the first run corresponded to the
binding mode of ZQU1305 in the cryo-EM structure (Figure 8B),
indicating that the subpocket occupied by this ligand entity
has a higher affinity toward ZQU than the subpocket occupied
by the ligand entity ZQU1304. In line with this, the pose
obtained for re-docking of ZQU1305 with ZQU1304 present was
scored markedly better than the pose obtained for re-docking of
ZQU1304 with ZQU1305 present (Glide Docking Scores:−10.40
and −8.60 kcal mol−1, respectively). Similarly, initial docking
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TABLE 3 | Sensitization of MCF-7/MX cells to mitoxantrone treatment by selected
3,4-dihydroisocoumarins.
Compound IC50 (µM) p-Value Fold change
Mitoxantrone 19.6 ± 2.4 – 1.00
+1 µM Ko143 0.3 ± 0.07∗∗∗∗ < 0.0001 65.33
+10 µM 16 21.1 ± 1.4 0.9795 0.93
+20 µM 16 5.3 ± 1.1∗∗∗∗ < 0.0001 3.70
+50 µM 16 3.5 ± 0.9∗∗∗∗ < 0.0001 5.60
+10 µM 14 19.4 ± 2.6 > 0.9999 1.01
+20 µM 14 25.5 ± 1.0 0.0942 0.77
+50 µM 14 25.0 ± 1.3 0.0988 0.78
Ko143 was used as positive control. Fold change of cytotoxicity was determined
by dividing the IC50 value of cells treated with mitoxantrone alone by the IC50
value of cells treated with mitoxantrone in combination with the respective test
compound. Data show mean ± SEM of three independent experiments performed
in quadruplicates. ∗∗∗∗p < 0.0001 compared to doxorubicin alone (one-way
ANOVA followed by Dunnett’s multiple comparisons test).
of the 3,4-dihydroisocoumarins revealed two spatially distinct
binding sites (BS1 and BS2) overlapping with those of ZQU1304
and ZQU1305, respectively, to which all ligands were docked
separately during the final docking experiment (Figure 8C).
Since, on average, the calculated effective binding energies were
7.44 ± 3.45 kcal mol−1 (21.64 ± 6.01 kcal mol−1 for the active
molecules 16, (R)-19 and (S)-19) more favorable in BS2 (Table 4),
only the poses in BS2 were used for the final evaluation.
The calculated effective binding energies of the 3,4-
dihydroisocoumarins agree very well with their ability to
inhibit P-gp-mediated transport: Compounds 16, 16a, (R)-19
and (S)-19, which all inhibited substrate transport by > 20% at
concentrations of 20 µM (Figure 2A), also showed significantly
more favorable effective binding energies than the inactive
compounds (1Geff = −48.16 ± 0.73 kcal mol−1 versus
1Geff = −31.81 ± 1.79 kcal mol−1, p < 10−4) (Figure 8C and
Table 4). Note, though, that configurational entropy differences
were neglected here, such that the difference in the binding
free energies of the two classes may be smaller due to enthalpy-
entropy compensation effects. These results validate the obtained
binding modes for the 3,4-dihydroisocoumarins in P-gp and
corroborate the experimental findings on the compounds’ ability
to inhibit P-gp-mediated substrate transport.
DISCUSSION
In this study, 3,4-dihydroisocoumarins, which have so far not
been in the focus as potential MDR reversing agents, were
evaluated as potential inhibitors of human and yeast ABC
transporters. Notably, among the tested derivatives, three novel
FIGURE 4 | Liquid drug assays of the 12 3,4-dihydroisocoumarins and S. cerevisiae strains expressing Pdr5 WT or the mutant Pdr5 EQ. (A) The influence of 14,
(R)-19, (S)-19, 3, 4, 21, and 16 on growth of strains expressing Pdr5 WT. (B) The influence of 14, (R)-19, (S)-19, 3, 4, 21, and 16 on growth of strains expressing
Pdr5 EQ. (C) The influence of (R)-19a, (S)-19a, 16a and ellagic acid on growth of strains expressing Pdr5 WT. (D) The influence of (R)-19a, (S)-19a, 16a and
ellagic acid on growth of strains expressing Pdr5 EQ. Cells were incubated at different concentrations of the compounds for 48 h at 30 ◦C and OD600
was determined.
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FIGURE 5 | Initial screening of the 12 test compounds to determine their effect on (A) the transport activity of Pdr5 WT and (B) their effect on the ATPase activity.
Within the transport assay compound 14, 3 and 4 had no effect on both activities. Compound 21, (R)-19a and (S)-19a were able to inhibit the transport activity to
around 50%. Only compound (R)-19, (S)-19, 16 and 16a were able to inhibit the transport activity of Pdr5 WT completely. In contrast, compounds 14, 3, 4, (R)-19a
and (S)-19a had nearly no effect on the ATPase activity. Compound 21 and ellagic acid were able to inhibit the ATPase activity of Pdr5 WT to 50%. Only
compound (R)-19, (S)-19, 16 and 16a were able to inhibit ATPase activity below 40% in comparison to Pdr5 WT in the absence of any compound.
FIGURE 6 | Determination of the transport IC50 values for (A) compound (R)-19, (B) compound (S)-19, (C) compound 16 and (D) compound 16a. For each
compound a serial dilution was used to determine the IC50 curve. Membranes were incubated with the compound and active transport was detected with the Tecan
Infinite M200.
3,4-dihydroisocoumarins were identified as dual inhibitors of
two human transporters, P-gp and BCRP. Furthermore, the
most potent inhibitor, derivative 16, demonstrated inhibition
of both transporters between 80 and 90% compared to the
respective positive controls at the highest test concentration
(50 µM). As proof of concept, P-gp expressing HCT-15 cells
and BCRP-expressing MCF-7/MX cells (Sachs et al., 2019)
were treated with compound 16 in combination with the
chemotherapeutic drugs doxorubicin and mitoxantrone,
broadly described as transporter substrates for P-gp and
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FIGURE 7 | Determination of the ATPase IC50 values for (A) compound (R)-19, (B) compound (S)-19, (C) compound 16 and (D) compound 16a. For each
compound a serial dilution was used to display the IC50 curve. Pdr5 plasma membranes (PMs) were incubated with the compound for 20 min and release of
inorganic phosphate was detected with an Elisa PlateReader at 595 nm.
BCRP. Subsequently, co-treatment with 50 µM of derivative
16 sensitized chemotherapy-resistant cancer cells HCT-15
colon carcinoma cells to doxorubicin by decreasing the IC50
value of doxorubicin-induced cytotoxicity by 3.7-fold and
sensitized MCF-7/MX breast carcinoma cells to mitoxantrone by
decreasing the IC50 value of mitoxantrone-induced cytotoxicity
by 5.6-fold. Moreover, enantiomers (R)-19 and (S)-19 inhibited
transport function of P-gp and BCRP, but with lower potency
compared to derivative 16. Noteworthy, distinct structure-
activity relationships for transporter inhibition could be
identified, and they run in parallel for P-gp and BCRP: our
data show that the hydroxy group at position 6 is mandatory
for transporter inhibition and substitution by a methoxy group
clearly reduces activity. Furthermore, a hydrophobic carbon
chain at position 3 is indispensable for inhibition and this
substituent seems to need a certain chain length. Compounds
without alkyl substituent (derivative 14) or with a methyl
group [6-methoxymellein (3) and angelicoin B (4)] as well as
compounds with a hydrophilic chain (derivatives (R)-19a and
(S)-19a) demonstrated significantly decreased inhibition of both
transporters. Those effects were more pronounced in BCRP
inhibition than in P-gp inhibition.
Molecular docking can provide an explanation at the atomistic
level for the observed structure-activity relationship. Here, we
focused on docking of 3,4-dihydroisocoumarins to P-gp because
for this system it was possible to validate the suitability of our
docking protocol. The predicted binding modes of the active
molecules 16, (R)-19 and (S)-19 close to the binding sites of
ZQU are largely identical (Figures 8D,E, 9A,B) and reveal
that the hydroxy group at position 8 stabilizes the binding
mode via hydrogen bonding to the hydroxy group in Y306.
Introduction of a bulky methyl group, as realized in 16a,
not only abolishes this interaction, but also leads to a steric
clash with Y306, forcing the molecule to invert its orientation
(Figure 9B). Furthermore, the hydrophobic OTBS moiety in
(R)-19 and (S)-19 protrudes into a predominantly hydrophobic
subpocket, formed by residues M298, N720, F769, Q772, Q837,
and V990. Removal of this group, as realized in (R)-19a and
(S)-19a, leads to an unsatisfied hydrogen bond donor in this
subpocket, which disfavors binding. Finally, compounds 3, 4,
14, 14a, and 21 adopt binding modes that either resemble the
inverted orientation of 16a, or are dissimilar to those of the active
molecules 16, (R)-19 and (S)-19 (Figure 9C). Taken together,
these results indicate that differences in the inhibitory power of
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FIGURE 8 | Molecular docking studies. (A) Re-docking of Zosuquidar (ZQU, darker turquoise, sticks representation) into the cryo-EM structure (PDB ID: 6FN1; Alam
et al., 2018) of P-gp (white, sticks and cartoon representation, only part of the protein is shown for clarity) while the coordinates of the respective second ZQU
molecule (lighter turquoise) were retained from the cryo-EM structure. (B) Sequential re-docking of ZQU into the cryo-EM structure of P-gp. The result of the first and
second runs are indicated with a 1 and 2, respectively. Colors and representations are as in (A). (C) Binding sites (denoted as BS1 and BS2) for
3,4-dihydroisocoumarins found during docking. The molecular structures of the 3,4-dihydroisocoumarins are displayed as lines, and their joint molecular surface is
rendered in white. Zosuquidar is shown as red sticks. The relevant region in the transmembrane domain of P-gp is shown in cartoon representation (D) Binding
mode of (R)-19 in BS2 of P-gp. Hydrogen bonds are displayed as yellow lines, pi-stacking interactions as green lines. (E) Relative effective binding energies for
3,4-dihydroisocoumarins in P-gp, calculated by the MM-GBSA approach. To allow for a better comparison with the P-gp transport assay, the energies are
expressed as −11Geff.
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TABLE 4 | Relative effective energies of 3,4-dihydroisocoumarins binding
to P-gp.1
Compound 11Geff2
BS1 BS2
14 −10.04 (−24.55) −14.16 (−28.67)
14a −14.85 (−29.36) −9.27 (−23.78)
16 −13.46 (−27.97) −32.80 (−47.31)
16a −24.12 (−38.63) −35.74 (−50.25)
(R)-19 −20.48 (−34.99) −32.48 (−46.99)
(R)-19a −22.61 (−37.12) −17.38 (−31.89)
(S)-19 0.00 (−14.51) −33.57 (−48.08)
(S)-19a −14.41 (−28.92) −20.96 (−35.47)
6-Methoxymellein (3) −12.62 (−27.13) −16.27 (−30.78)
Angelicoin B (4) −20.66 (−35.17) −23.83 (−38.34)
21 −20.56 (−35.02) −19.23 (−33.74)
1All values are relative to the effective binding energy of (S)-19 in BS1.
2 In kcal mol−1.
FIGURE 9 | Comparison of binding poses of 3,4-dihydroisocoumarins in P-gp
obtained by molecular docking. (A) Binding poses of compounds carrying a
TBS group in the side chain [(R)-19, (S)-19] versus compounds in which the
TBS group was removed [(R)-19a, (S)-19a]. (B) Binding poses of compounds
that carry a hydroxy group at position 8 [(R)-16, (S)-16] versus compounds
that carry a methoxy group at position 8 [(R)-16a, (S)-16a]. (C) Binding
modes of compounds 3, 4, 14, 14a, and 21 in comparison to (R)-19
and (S)-19.
the investigated 3,4-dihydroisocoumarins with respect to P-gp-
mediated transport result from differences in the compounds’
binding affinities to P-gp rather than their ability to modulate
P-gp’s transport cycle or to affect P-gp function via a different
mechanism. They further support the recent finding (Alam et al.,
2018) that the central cavity in P-gp can accommodate multiple
molecules in different subpockets and, thereby, substantiate the
concept of a binding site with high plasticity (Wise, 2012;
McCormick et al., 2015).
Regarding these results, the 3,4-dihydroisocoumarin
derivatives that we identified as dual P-gp and BCRP
inhibitors with moderate activity might serve as a promising
starting point for further development of novel inhibitors for
overcoming cancer MDR. In future work, it will be important
to identify additional substituents at other positions of the
molecule to significantly improve the potency of the current
chemical lead structure.
In a first initial screening (R)-19, (S)-19, 16 and 16a were
identified as potential inhibitors of the yeast ABC transporter
Pdr5. With these four compounds IC50 measurements with
respect to R6G transport as well as the ATPase activity were
performed. In the case of the transport assay the highest
IC50 value was determined for (R)-19 with 26.0 ± 3.5 µM.
Interestingly the lowest IC50 was detected for its enantiomer (S)-
19 with 5.3 ± 0.6 µM. The transport IC50 values for 16 and
16a were nearly similar with 15.1 ± 2.1 and 14.6 ± 3.9 µM,
respectively. For the ATPase activity it was not possible to
reliably determine any IC50 value because of the limited solubility
of the compounds. The highest ATPase activity inhibition of
Pdr5 wild-type was detected for (S)-19 with an inhibition down
to 17.3% activity in comparison to Pdr5 WT without any
compound. For (R)-19 the ATPase activity was inhibited to
21.5% and for 16 and 16a the activity was inhibited to 35.4
and 22.8%, respectively. Our data furthermore suggest that these
four coumarins are substrates of Pdr5, which are transported
in competition to the fluorophore R6G and become inhibitory
at higher concentrations, a phenomena often observed for P-gp
(Al-Shawi et al., 2003) and Pdr5 (Ernst et al., 2008). In contrast
to P-gp, it is obviously not important if there is a hydroxy or
methoxy group at position 6, but it seems important that a longer
hydrophobic side chain is present at position 3. The two natural
substrates 6-methoxymellein (3) and angelicoin (4) with only
a small methyl group at position 3 or compound 14 with no
alkyl side chain at all displayed no effect on neither transport
nor ATPase activity. Furthermore, in comparison to that the two
compounds with a longer alkyl side chain with a hydrophilic
group ((R)-19a and (S)-19a) showed only inhibition to around
40%. In addition to transporter inhibition, the cytotoxic activity
of the test compounds was analyzed in sensitive A549 lung
carcinoma cells as well as resistant HCT-15 colon carcinoma,
H69AR lung carcinoma and MCF-7/MX breast carcinoma cells.
Most compounds did not exhibit any toxic effects in cancer cells.
One exception was derivative 16a, which proved to be selectively
cytotoxic in BCRP-expressing MCF-7/MX cells with an IC50
value of 10.6 µM, but not in P-gp or MRP1-expressing cells.
In sensitive A549, cytotoxicity was significantly lower with an
IC50 value of 53.6 µM. At this point, it would be interesting to
further characterize if compound 16a specifically kills multidrug-
resistant cells by analyzing its activity in parental, sensitive MCF-
7 cells. If this is the case, gaining insights into the mechanism
of action and target would be helpful to find out more about
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collateral sensitivity in BCRP-overexpressing cancer cells and
how to exploit this feature in tumor therapy (Pluchino et al., 2012;
Rao et al., 2014).
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